Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In this paper we present a 10-year-boy with viral giant-cell hepatitis with a immune component. We observed clinical, biochemical and histological improvement after treatment.
Pediatr Pol 1995 May
PMID:[Giant-cell hepatitis in a 10-year-old boy]. 869 99

In 49 prematures (25 infected and 24 healthy) serum cholesterol and triglycerides concentrations, value of alpha, pre-beta and beta serum lipoproteins (by electrophoresis) and activity of AspAt, AlAt and GGTP were estimated. It was stated, that the mean serum cholesterol concentration at the beginning of infection was significantly lower than in healthy babies, but in 2-3 week of disease the mean value of this parameter was significantly higher than in first week of life. Mean value of alpha lipoprotein was significantly lower, mean value of pre-beta and beta lipoproteins were higher in sick prematures than in control. In septic prematures positive correlation between the high serum cholesterol concentration and activity of GGTP and AspAt was found. In 30% of all septic neonates hepatitis and in 65% of dead infected prematures structural damage of liver were noted.
Ginekol Pol 1995 Nov
PMID:[Evaluation of selected lipid metabolism parameters in premature infants with infections]. 869 53

Transcription and replication of hepatitis delta virus (HDV) RNA are performed by the cellular enzyme RNA polymerase II (Pol II). As DNA is the normal template for Pol II, the enzyme must undergo template switching. The mechanism for this is unknown, but since HDV RNA can form a rod-like molecule by extensive intramolecular base pairing, it has been suggested that a double-stranded region(s) of HDV RNA serves as a recognition site for Pol II. A bidirectional promoter has been identified previously on HDV cDNA (T. B. Macnaughton, M. R. Beard, M. Chao, E. J. Gowans, and M. M. C. Lai, Virology 196:629-636, 1993). In the present study, genomic RNA corresponding to this region was able to direct the synthesis of antigenomic RNA in a nuclear extract transcription reaction, whereas genomic RNA species containing a mutation that resulted in a replication-defective phenotype were unable to do so. Thus, this region, the location of which is defined as nucleotides 1608 to 1669 on the basis of a highly conserved structure, represents a RNA-RNA promoter. Computer analysis of the RNA secondary structure predicted that the promoter contains two bulge regions in a stem-loop structure which encompasses a GC-rich motif. This predicted model was confirmed by enzyme digestion and primer extension analysis. The promoter is located at one end of the rod and has some homology with the simian virus 40 late promoter. A number of other mutations were introduced within this region, and expression plasmids were constructed to examine the effects of mutations in the promoter on HDV replication. Disruption of the overall secondary structure, particularly the bulge regions, totally inhibited HDV RNA replication.
 ...
PMID:Identification and characterization of a hepatitis delta virus RNA transcriptional promoter. 876 5

1.286 patients were diagnosed as DIC, among 123.231 patients who were admitted in the 285 departments of the university hospitals in Japan, in 1992. The incidence of DIC was high in acute promyelocytic leukemia, fulminant hepatitis, abruptio placentae, acute respiratory distress syndrome, and sepsis. In cases of DIC, bleeding tendency due to consumption coagulopathy is most important, but organ dysfunction due to circulatory disturbances by development of multiple thrombi is also noteworthy. As a whole, DIC may be divided in two types. The first type is cases of DIC with severe bleeding symptoms. However, except cerebral hemorrhage, organ dysfunction is rare in these cases. These cases may be called as "fibrinolysis-dominant DIC", because hemostatic thrombi as well as thrombi which cause organ dysfunction by circulatory disturbances are rapidly removed by abnormally enhanced fibrinolysis. The second type involves cases of DIC with severe organ dysfunction. Bleeding symptoms in these cases are usually not severe. These cases may be called as "coagulation-dominant DIC". The most typical causative disease of the fibrinolysis-dominant DIC is acute promyelocytic leukemia. The most typical causative disease of the coagulation-dominant DIC is sepsis. The presence of causative disease of DIC, elevation of FDP, and depletion of platelet count are most important to diagnose DIC. In the treatment of DIC, removal of cause of DIC, administration of heparin to protect further development of multiple thrombi, and replacement of platelets in cases of acute leukemia are most important.
Pol J Pharmacol
PMID:Clinical aspects of DIC--disseminated intravascular coagulation. 911 31

Epidemiological evaluations indicate an increase of acute viral hepatitis B in children. In this study authors performed an analysis of disease prognosis in retrospective trial in children hospitalized in the Pediatric Department of Infectious Diseases from 1983 to 1993 because of acute viral hepatitis B. It was documented that a risk of persistent hepatitis B may be related to the age of patients with acute viral hepatitis B in the past. In 64% of analyzed patients below 1 year old and in 20% over 6 years-persistent hepatitis was diagnosed, especially in male subjects.
Pol Merkur Lekarski 1996 Sep
PMID:[Prognosis in acute viral hepatitis B in children]. 913 84

The presence of serum autoantibodies directed against single-stranded DNA (ssDNA), RNA, histones, nuclear antigen SS-A, mitochondria and cardiolipin were investigated in 30 HIV-negative drug addicts (from years 1986-87), 30 addicts actually infected with HIV and 31 AIDS patients presenting with clinical symptoms indicating autoimmune disorders. Positive results were found in 12 (40%) drug addicts from years 1986-87, 5 (16.7%) actually infected and 16 (51.6%) AIDS patients. Autoantibodies were more often detectable in patients with thrombocytopenia 8/12 (66.7%) than in remaining 8 out of 19 subjects (42.1%) who presented dermatitis, hepatitis, pancarditis, ulcerative colitis and polyneuropathy. The prevalence of autoantibodies in all investigated groups were significantly higher than in controls-1/20 (3.3%).
Pol Merkur Lekarski 1996 Oct
PMID:[Presence of autoantibodies in patients infected with HIV]. 915 38

The patients with chronic congestive heart failure and acute deterioration of heart failure (pulmonary oedema, significant reduction of blood pressure) have decrease liver's perfusion with signs of acute damage of liver's cells--ischemic hepatitis. Aspat, AIAT and LDH in blood rich very high level. The level of bilirubin, alkaline phosphatase and glucose increase slightly. Hepatotoxic viruses are never observed. The authors described a case of 34 years old man, who two years earlier had large myocardial infarction with aneurysm of heart and congestive heart failure. He was admitted to hospital in shock. The shock was caused probably by overdose of nitroglycerin. In ECG and Echo examinations he had no signs of acute myocardial infarction, but we observed serious damage of liver's cells with very high levels of AspAT, AIAT and LDH. Based on clinical and biochemical examinations we diagnosed ischemic hepatitis. The patient's clinical and biochemical tests were normalized after improvement of heart failure. Biopsy of liver was normal at that time. Prognosis in ischemic hepatitis depends on course of heart failure.
Pol Merkur Lekarski 1997 Dec
PMID:[Ischemic hepatitis]. 952 68

Report a case of a girl with HGV-RNA in the serum, which was detected during the treatment of autoimmune hepatitis. Infection HGV may cause aminotransferases abnormalities because they were elevated despite of the 2.5-year immunosuppressive therapy.
Pol Merkur Lekarski 1999 Feb
PMID:[Coexistent hepatitis G virus infection and autoimmune hepatitis]. 1033 78

Hepatitis C virus, a small enveloped RNA member of Flaviviridae, is the major causative agent of non-A, non-B hepatitis. The discovery and genetic characterization of HCV is described. Modern genetic procedures and methods involved in the studies of HCV biology, genetic heterogenity and diagnostics of HCV infections are presented. Interferon-alfa treatment is the only licensed therapy for chronic hepatitis C until now, but an efficacy of such treatment is highly variable. Viral factors predicting the long-term outcome of interferon alfa therapy, such as genotype, baseline viral load, quasispecies or ISDR mutations, and current concepts of their predictive values are discussed. Our own results are presented and compared with those present in the latest publications.
Pol Merkur Lekarski 1999 Feb
PMID:[Genetic diagnosis of hepatitis C virus infection]. 1033 82

The 2',3'-cyclic phosphate termini are produced, as either intermediates or final products, during RNA cleavage by many different endoribonucleases. Likewise, ribozymes such as hammerheads, hairpins, or the hepatitis delta ribozyme, generate 2',3'-cyclic phosphate ends. Discovery of the RNA 3'-terminal phosphate cyclase has indicated that cyclic phosphate termini in RNA can also be produced by an entirely different mechanism. The RNA 3'-phosphate cyclase converts the 3'-terminal phosphate in RNA into the 2',3'-cyclic phosphodiester in the ATP-dependent reaction which involves formation of the covalent cyclase-AMP and the RNA-N3' pp5' A intermediates. The findings that several eukaryotic and prokaryotic RNA ligases require the 2',3'-cyclic phosphate for the ligation of RNA molecules raised a possibility that the RNA 3'-phosphate cyclase may have an anabolic function in RNA metabolism by generating terminal cyclic groups required for ligation. Recent cloning of a cDNA encoding the human cyclase indicated that genes encoding cyclase-like proteins are conserved among Eucarya, Bacteria, and Archaea. The protein encoded by the Escherichia coli gene was overexpressed and shown to have the RNA 3'-phosphate cyclase activity. This article reviews properties of the human and bacterial cyclases, their mechanism of action and substrate specificity. Possible biological functions of the enzymes are also discussed.
Acta Biochim Pol 1998
PMID:Cyclases of the 3'-terminal phosphate in RNA: a new family of RNA processing enzymes conserved in eucarya, bacteria and archaea. 1039 37


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>